Provided by: Mycenax Biotech Inc. Finacial year: Yearly Unit: NT\$ thousand

Accounting Title	2016/06/30	2015/12/31	2015/06/30
Balance Sheet	l .		
Current assets			
Total cash and cash equivalents	406,372	305,619	432,00
Total Current investments in debt instrument without active market	510,850		809,96
Notes receivable due from related parties, net	310,030		009,90
Accounts receivable, net	9,232	18,570	7,617
Other receivables, net	2,746	·	14,042
Total current tax assets	2,740	·	
		·	3,404
Total inventories	54,222	22,627	20,669
Total prepayments	45,467	21,576	15,748
Total other current assets	19,287	9,323	1,12
Total current assets	1,050,562	1,244,583	1,304,56
Non-current assets			
Total Non-current investments in debt instrument without active market	30,000		30,00
Total property, plant and equipment	274,969		190,42
Total intangible assets	1,100		1,19
Deferred tax assets	39,540	40,173	39,92
Total other non-current assets	57,111	3,174	3,45
Total non-current assets	402,720	273,803	264,99
Total assets	1,453,282	1,518,386	1,569,55
Current liabilities			
Total accounts payable	46,249	19,619	15,76
Total accounts payable to related parties	0	40	1
Total other payables	39,786	30,362	21,71
Total other current liabilities	14,152	11,618	9,15
Total current liabilities	100,187	61,639	46,64
Non-current liabilities		,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,	-,-
Total deferred tax liabilities	362	796	
Total other non-current liabilities	1,714	1,737	3,03
Total non-current liabilities	2,076		3,03
Total liabilities	102,263	·	49,67
Share capital	102,200	04,172	40,01
Ordinary share	1,118,180	1,115,990	1,110,73
Advance receipts for share capital	2,349	, ,	5,54
Total share capital			
	1,120,529	1,110,201	1,116,27
Capital surplus	040 404	044.004	000.40
Total capital surplus, additional paid-in capital	618,481	614,631	606,18
Capital surplus, treasury share transactions	2,812	2,812	2,81
Capital surplus, employee share options	7,070		
Total capital surplus	628,363	621,319	615,99
Retained earnings			
Total unappropriated retained earnings (accumulated deficit)	-310,262		
Total retained earnings	-310,262	-197,695	-177,98
Other equity interest			
Total revaluation surplus	0	0	(
Total other equity, others	0	0	1
Total other equity interest	0	0	
Treasury shares	-87,611	-87,611	-34,40
Equity attributable to former owner of business combination under common control	0	0	•
Equity attributable to non-controlling interest before business combination under common control	0	0	
Total equity	1,351,019	1,454,214	1,519,88
Total liabilities and equity	1,453,282		1,569,55
Number of share capital awaiting retirement	1,435,202		1,000,00
Equivalent issue shares of advance receipts for ordinary share	120,500	ű	266,50
Number of shares in entity held by entity and by its subsidiaries	2,200,000		

Provided by: Mycenax Biotech Inc.

Finacial year: Yearly
Unit: NT\$ thousand

Accounting Title	2016/2nd	2015/2nd	2016/01/01To2016/06/30	2015/01/01To2015/06/30
Income Statement			<u>.</u>	
Total operating revenue	30,060	7,764	40,029	19,749
Total operating costs	39,351	26,230	70,008	42,023
Gross profit (loss) from operations	-9,291	-18,466	-29,979	-22,274
Gross profit (loss) from operations	-9,291	-18,466	-29,979	-22,274
Operating expenses				
Total selling expenses	2,375	1,215	4,460	1,802
Total administrative expenses	7,733	11,053	14,811	17,671
Total research and development expenses	47,910	31,080	88,986	63,510
Total operating expenses	58,018	43,348	108,257	82,983
Net operating income (loss)	-67,309	-61,814	-138,236	-105,257
Non-operating income and expenses				
Total other income	14,675	10,154	28,046	20,926
Other gains and losses, net	101	-1,111	-2,178	-5,421
Total non-operating income and expenses	14,776	9,043	25,868	15,505
Profit (loss) from continuing operations before tax	-52,533	-52,771	-112,368	-89,752
Total tax expense (income)	134	211	199	298
Profit (loss) from continuing operations	-52,667	-52,982	-112,567	-90,050
Profit (loss)	-52,667	-52,982	-112,567	-90,050
Total comprehensive income	-52,667	-52,982	-112,567	-90,050
Basic earnings per share				
Total basic earnings per share	-0.48	-0.48	-1.03	-0.81

Provided by: Mycenax Biotech Inc. Finacial year: Yearly Unit: NT\$ thousand

Accounting Title	2016/01/01To2016/06/30	2015/01/01To2015/06/30
Statements of Cash Flows		
Cash flows from (used in) operating activities, indirect method		
Profit (loss) from continuing operations before tax	-112,368	-89,75
Profit (loss) before tax	-112,368	-89,75
Depreciation expense	19,329	16,67
Amortization expense	447	67
Provision (reversal of provision) for bad debt expense	0	÷:
Interest income	-4,753	-7,71
Share-based payments	5,040	59
Impairment loss on non-financial assets	55	7
Other adjustments to reconcile profit (loss)	0	·
Total adjustments to reconcile profit (loss)	20,118	10,30
Decrease (increase) in notes receivable	71	10,00
Decrease (increase) in accounts receivable	9,338	32,52
Decrease (increase) in accounts receivable due from related parties	0,000	4,92
Decrease (increase) in other receivable	-186	-5,84
Decrease (increase) in inventories	-31,650	-5,77
Decrease (increase) in prepayments	-23,891	-3,18
Decrease (increase) in other current assets	-1,256	-21
Total changes in operating assets	-47,574	22,43
Increase (decrease) in accounts payable	26,630	4,32
Increase (decrease) in accounts payable to related parties	-40	-1
Increase (decrease) in other payable	-3,082	-6,16
Increase (decrease) in other current liabilities	2,534	-6,26
Increase (decrease) in net defined benefit liability	-23	6,25
Total changes in operating liabilities	26,019	-8,03
Total changes in operating assets and liabilities	-21,555	14,39
Total adjustments	-1,437	24,70
Cash inflow (outflow) generated from operations	-113,805	-65,04
Income taxes refund (paid)	1,652	-67
Net cash flows from (used in) operating activities	-112,153	-65,72
Cash flows from (used in) investing activities	112,100	00,12
Acquisition of investments in debt instrument without active market	-213,121	-839,71
Proceeds from disposal of investments in debt instrument without active market	562,138	1,155,50
Increase in prepayments for investments	-20,000	1,100,00
Acquisition of property, plant and equipment	-81,774	-38,53
Increase in refundable deposits	439	-13
Acquisition of intangible assets	-287	-10
Increase in other financial assets	-8,708	
Increase in prepayments for business facilities	-35,198	-35
Interest received	5,085	7,57
Net cash flows from (used in) investing activities	208,574	284,34
Cash flows from (used in) financing activities	200,011	201,01
Proceeds from issuing shares	0	
Exercise of employee share options	4,332	6,64
Payments to acquire treasury shares	1,002	-32,11
Net cash flows from (used in) financing activities	4,332	-25,47
Effect of exchange rate changes on cash and cash equivalents	1,002	-20,47
let increase (decrease) in cash and cash equivalents	100,753	193,14
Cash and cash equivalents at beginning of period	305,619	238,85
Cash and cash equivalents at beginning of period	406,372	432,00
Cash and cash equivalents at end of period  Cash and cash equivalents reported in the statement of financial position	406,372	432,00
Other items qualifying for cash and cash equivalents under the definition of IAS 7	406,372	432,00

Financial Statement — Statements of Changes in Stockholders' Equity

Provided by: Mycenax Biotech Inc. Finacial year: Yearly Unit: NT\$ thousand

2016/06/30	Statement of Stockholders' Equity

										o =quity				
								Unit: NT\$ thousand						
Accounting Title	Ordinary share Advan	nce receipts for share capi	ital Total share capital	Capital surplus Una	appropriated retained earnings (accumulated deficit) Total retainer	d earnings E	.xchange differences on translation of foreign financial statemer	nts Gains (losses) from investments in equity instruments measured at fair value through other comprehensive income Unrealized gains (losses) on available-for-sale financial asset	s Gains (losses) on effective portion of cash flow hedges Gains (losses) on effective	portion of hedges of net investments in foreign operations Change in fair value of financial liability attributable	e to change in credit risk of liability Gains (losses) on remeasurements of defined bene	fit Revaluation surplus Equity rel	lated to non-current assets classified as held for sale Others Total other equity interest	t Treasury shares Total equity
Equity at beginning of period	1,115,990	2,2	211 1,118,201	621,319	-197,695	-197,695		0	0	0	0	0 0	0 0	-87,611 1,454,214
Equity at beginning of period after adjustments	1,115,990	2,2	211 1,118,201	621,319	-197,695	-197,695		0	0	0	0	0 0	0 0	-87,611 1,454,214
Profit (loss)	0		0 0	0	-112,567	-112,567		0	0	0	0	0 0	0 0	0 -112,567
Other comprehensive income	0		0 0	0	0	0		0	0	0	0	0 0	0 0	0 0
Total comprehensive income	0		0 0	0	-112,567	-112,567		0	0	0	0	0	0 0	0 -112,567
Share-based payments	2,190	1	138 2,328	7,044	0	0		0	0	0	0	0	0 0	0 9,372
Total increase (decrease) in equity	2,190	1	138 2,328	7,044	-112,567	-112,567		0	0	0	0	0	0 0	0 -103,195
Equity at end of period	1,118,180	2,3	349 1,120,529	628,363	-310,262	-310,262		0	0	0	0	0 0	0 0	-87,611 1,351,019
			Accounting Title	T.	Coding about the second state of the second st			2015/06/30 Statement of Stock Unit: NT\$ thousand	kholders' Equity		not investments in fareign exerctions Equity related to non-current accepts alongified or	hald for a shall Others Tatal allow	and the internal Transport of the land	

Accounting Title Ord	dinary share Advance receipts	s for share capital Total sha	are capital Ca	apital surplus Unappropriated retained earnings (accumulate	ed deficit) Total retained ea	arnings Exchange differences on translation of foreign financial statements Gains (losses) from investments in equity instruments measured at fair value through other comprehensiv	e income Unrealized gains (losses) on available-for-sale financial assets Gains (losses) on effective portion of cash flow he	dges Gains (losses) on effective portion of hedges of net investments in foreign operations Equity related to non-current assets classified as held for sale Oth	ers Total other equity intere	est Treasury shares Total ec
Equity at beginning of period	1,109,260	1,660	1,110,920	614,121	-87,935	-87,936 0	0 0	0 0	0	0 0 1,637
Effects of retrospective application and retrospective restatement	0	0	0	0	0	0	0 0	0 0	0	0 0
Equity at beginning of period after adjustments  Profit (loss)  Other comprehensive income	1,109,260	1,660	1,110,920	614,121	-87,935	-87,935 0	0 0	0 0	0	0 0 1,637
Profit (loss)	0	0	0	0	-90,050	-90,050 0	0	0 0	0	0 0 -90
Other comprehensive income	0	0	0	0	0	0	0 0	0 0	0	0 0
Total comprehensive income Purchase of treasury share Share-based payments Total increase (decrease) in equity	0	0	0	0	-90,050	-90,050 0	0 0	0 0	0	0 0 -90
Purchase of treasury share	0	0	0	0	0	0	0	0 0	0	0 -34,406 -34
Share-based payments	1,470	3,888	5,358	1,874	0	0	0	0 0	0	0 0 7
Total increase (decrease) in equity	1,470	3,888	5,358	1,874	-90,050	-90,050	0	0 0	0	0 -34,406 -117
Equity at end of period	1,110,730	5,548	1,116,278	615,995	-177,985 -	177,985	0	0 0	0	0 -34,406 1,519